Skip to content

Tango Therapeutics

US · TNGX #2322 by market cap Listed 1970
21.73 -0.98 -4.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:41

Recent news

  • Rating change
    Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/8/12
  • Rating change
    Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/6/26
  • J.P. Morgan Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $47
    Market Newswire · 2026/11/10
  • Rating change
    H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/8/18
  • CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46
    Market Newswire · 2026/11/10
  • Rating change
    H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $68
    Market Newswire · 2026/10/29
  • Rating change
    Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $55
    Market Newswire · 2026/10/24
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)
    TipRanks · 2026/8/12
  • Rating change
    William Blair Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $42
    Market Newswire · 2026/10/16
  • Rating change
    CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/6/11
  • Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/11/10
  • Rating change
    Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/6/26
  • Rating change
    H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/6/11
  • Rating change
    CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46
    Market Newswire · 2026/6/29
  • Rating change
    J.P. Morgan Maintains Tango Therapeutics(TNGX.US) With Buy Rating
    Market Newswire · 2026/10/13
  • Earnings Flash (TNGX) Tango Therapeutics Posts Q3 Loss $0.39 a Share, Vs. FactSet Est of $0.35 Loss
    MT Newswires · 2026/11/9
  • A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $67
    Market Newswire · 2026/11/10
  • Rating change
    Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/8/17
  • Rating change
    Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39
    Market Newswire · 2026/8/12
  • Rating change
    J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46
    Market Newswire · 2026/7/15
  • CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46
    Market Newswire · 2026/10/12
  • Rating change
    A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66
    Market Newswire · 2026/6/10
  • Rating change
    A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $42
    Market Newswire · 2026/6/9
  • Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/9/24
  • Rating change
    CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/5/22

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:41:45 · For reference only, not investment advice and not tailored to your situation.

Tango Therapeutics discussion 0 comments

Add a comment